Phenylbutazone -loaded nanoparticulate emulgel for the management of rheumatic arthritis: Formulation, optimization, and in vitro evaluation

Rheumatoid arthritis is a chronic autoimmune inflammatory disorder requiring long-term therapy that is frequently associated with systemic adverse effects. The present study aimed to develop and characterize a nanoparticulate emulgel containing Phenylbutazone (PBZ) for topical delivery to manage pain and swelling associated with rheumatoid arthritis. PBZ-loaded chitosan nanoparticles were prepared by the ionic gelation method followed by ultrasonication. Drug-excipient compatibility was evaluated by Fourier Transform Infrared (FTIR) spectroscopy, and nanoparticles were optimized by Box-Behnken design comprising 15 experimental runs. The nanoparticles were characterized for particle size, encapsulation efficiency, and in vitro drug release, while the emulgel was characterized for pH, viscosity, drug content, surface morphology by scanning electron microscopy (SEM), and an in vitro protein denaturation inhibitory activity. The prepared nanoparticles showed a particle size range of 229–502 nm with an encapsulation efficiency exceeding 61-91%. In vitro drug release studies demonstrated cumulative drug release of 76.68 ± 2.05% and 90.52 ± 2.32% at pH 7.4 and 5.5, respectively, over 72 hours. The optimized emulgel formulation exhibited a pH of 6.7 ± 0.30, viscosity of 20,000 ± 700 mPa · s, and a drug content of 90.23 ± 7.47%. SEM analysis confirmed spherical nanoparticles with an average particle size of approximately 211 nm. In vitro protein denaturation inhibition assay revealed that the prepared emulgel inhibited protein denaturation by 71.88 ± 4.74%, compared with 75.63 ± 5.41% for the standard drug, demonstrating a significant difference (<0.025). The developed PBZ-loaded chitosan nanoparticulate emulgel demonstrated favorable physicochemical characteristics, sustained drug release, and suggested its potential as an effective anti-inflammatory topical therapeutic system for the management of rheumatoid arthritis.

Authors

Publication Details

Journal
Journal of Biomaterials Applications
Published
2026-11-19
DOI
https://doi.org/10.1177/08853282261507873
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phenylbutazone -loaded nanoparticulate emulgel for the management of rheumatic arthritis: Formulation, optimization, and in vitro evaluation

Veena Devi Singh, Nagendra Bhuwane, Rameshroo Kenwat, Ankita Gupta et al.
Journal of Biomaterials Applications
Advancements in Transdermal Drug Delivery
article

Phenylbutazone -loaded nanoparticulate emulgel for the management of rheumatic arthritis: Formulation, optimization, and in vitro evaluation

Veena Devi Singh, Nagendra Bhuwane, Rameshroo Kenwat, Ankita Gupta, Vijay Kumar Singh
article en

Abstract

Rheumatoid arthritis is a chronic autoimmune inflammatory disorder requiring long-term therapy that is frequently associated with systemic adverse effects. The present study aimed to develop and characterize a nanoparticulate emulgel containing Phenylbutazone (PBZ) for topical delivery to manage pain and swelling associated with rheumatoid arthritis. PBZ-loaded chitosan nanoparticles were prepared by the ionic gelation method followed by ultrasonication. Drug-excipient compatibility was evaluated by Fourier Transform Infrared (FTIR) spectroscopy, and nanoparticles were optimized by Box-Behnken design comprising 15 experimental runs. The nanoparticles were characterized for particle size, encapsulation efficiency, and in vitro drug release, while the emulgel was characterized for pH, viscosity, drug content, surface morphology by scanning electron microscopy (SEM), and an in vitro protein denaturation inhibitory activity. The prepared nanoparticles showed a particle size range of 229–502 nm with an encapsulation efficiency exceeding 61-91%. In vitro drug release studies demonstrated cumulative drug release of 76.68 ± 2.05% and 90.52 ± 2.32% at pH 7.4 and 5.5, respectively, over 72 hours. The optimized emulgel formulation exhibited a pH of 6.7 ± 0.30, viscosity of 20,000 ± 700 mPa · s, and a drug content of 90.23 ± 7.47%. SEM analysis confirmed spherical nanoparticles with an average particle size of approximately 211 nm. In vitro protein denaturation inhibition assay revealed that the prepared emulgel inhibited protein denaturation by 71.88 ± 4.74%, compared with 75.63 ± 5.41% for the standard drug, demonstrating a significant difference (<0.025). The developed PBZ-loaded chitosan nanoparticulate emulgel demonstrated favorable physicochemical characteristics, sustained drug release, and suggested its potential as an effective anti-inflammatory topical therapeutic system for the management of rheumatoid arthritis.

Journal of Biomaterials Applications
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon